In the 2024 European Association of Urology (EAU) guidelines for the diagnosis and treatment of prostate cancer, it is noted that the currently recognized postoperative residual PSA primarily originates from three pathways: undetected systemic tumor micro-metastasis prior to surgery, residual localized prostate cancer tissue, and benign prostate tissue remnants. Here, KLK3 is linked to prostate cancer.